P27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients

International Journal of Cancer

Volumn 127, Issue 12, 2010, Pages 2851-2858

  Stendahl, Maria ^a   Nilsson, Sofie ^a,b   Wigerup, Caroline ^a   Jirström, Karin ^a   Jönsson, Per Ebbe ^c   Stal, Olle ^d   Landberg, Göran ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Breast cancer; ER; P27 Kip1; Prognosis; Tamoxifen response

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; TAMOXIFEN; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CDKN1B PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; BREAST TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; PREMENOPAUSE; RECEPTORS, ESTROGEN; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78249249610     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25297     Document Type: Article

References (28)

1. Morgan DO,. Principles of CDK regulation. Nature 1995; 374: 131 -4.
2. Cariou S, Catzavelos C, Slingerland JM,. Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. Breast Cancer Res Treat 1998; 52: 29 -41.
3. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ,. The p21(Cip1) and p27(Kip1) CDK inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999; 18: 1571 -83.
4. Larrea MD, Liang J, Da Silva T, Hong F, Shao SH, Han K, Dumont D, Slingerland JM,. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol 2008; 28: 6462 -72.
5. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E,. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997; 11: 847 -62.
6. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227 -30.
7. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM,. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222 -5.
8. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M,. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997; 57: 1259 -63.
9. Chu IM, Hengst L, Slingerland JM,. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253 -67.
10. Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, et al. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006; 98: 1723 -31.
11. Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC, Lee MH,. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 2001; 30: 169 -75.
12. Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, et al. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res 2009; 15: 2116 -22.
13. Lee KH, Lee HE, Cho SJ, Cho YJ, Lee HS, Kim JH, Nam SY, Chang MS, Kim WH, Lee BL,. Immunohistochemical analysis of cell cycle-related molecules in gastric carcinoma: prognostic significance, correlation with clinicopathological parameters, proliferation and apoptosis. Pathobiology 2008; 75: 364 -72.
14. Tsoli E, Gorgoulis VG, Zacharatos P, Kotsinas A, Mariatos G, Kastrinakis NG, Kokotas S, Kanavaros P, Asimacopoulos P, Bramis J, Kletsas D, Papavassiliou AG, et al. Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas. Mol Med 2001; 7: 418 -29.
15. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM,. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58: 542 -8.
16. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K,. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707 -20.
17. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM,. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996; 85: 733 -44.
18. Ryden L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K, Kallstrom AC, Landberg G, Stal O, Thorstenson S, Nordenskjold B,. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005; 41: 256 -64.
19. Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M,. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 2003; 21: 3594 -600.
20. Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K,. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006; 12: 4614 -18.
21. Alkarain A, Jordan R, Slingerland J,. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 2004; 9: 67 -80.
22. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G,. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005; 65: 8009 -16.
23. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A,. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381 -5.
24. Singh SP, Lipman J, Goldman H, Ellis FH, Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M,. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998; 58: 1730 -5.
25. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C,. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995; 9: 2364 -72.
26. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM,. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004; 10: 5670 -6.
27. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G,. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006; 98: 671 -80.
28. Ahnstrom M, Nordenskjold B, Rutqvist LE, Skoog L, Stal O,. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 2005; 91: 145 -51.